Every material Form 8-K BIOVIE INC. filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
At its November 10, 2025 annual meeting, BioVie's stockholders approved an amended and restated 2019 Omnibus Equity Incentive Plan, effective that day. The amendment raises the number of common shares authorized for issuance under the plan to 3,100,000, allowing the company to keep granting equity compensation to employees, directors and consultants.
Stockholders approved the amended and restated 2019 Omnibus Equity Incentive Plan on November 10, 2025, effective the same day.
Authorized shares under the plan increased to 3,100,000 common shares.
Full plan terms are in Appendix A to the Definitive Proxy Statement on Schedule 14A filed September 25, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every BIOVIE INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →